Mirtazapine
Material: | 1 ml serum |
Methods: | Flüssigkeitschromatographie-Massenspektrometrie (LC-MS/MS) → LC-Tandem-Massenspektrometrie |
Indication | Therapeutic drug monitoring |
Therapeutic range | 30 µg/l – 80 µg/l > 160 µg/l toxic |
Please note | Mirtazapine is a tetracyclic antidepressant. It acts primarily through an antagonism at the presynaptic alpha-2 receptor and thereby enhances the noradrenergic signaling. In addition, it acts serotonergic via the 5-HT1 receptor while simultaneously inhibiting the 5-HT2 and 5-HT3 receptors. The sedative effect of mirtazapine is caused by the inhibition of the histamine H1 receptors. The side effect spectrum primarily comprises of tiredness and weight loss due to an increase in appetite, in rare cases there may be granulocytopenia. |
Accredited | ja |
More Results for the letter M
- Methylmalonic acid (METHYS)
- Methylphenidate (METHE)
- Ritalin
- Metoprolol (METO)
- Microglobulin (α1-) (MICR04(a1))
- Microsporidia (MICR05)
- of about 100 genii of microsporidia only 5 have a pathogenic significance for humans, among them the Encephalitozoon und Enterocytozoon
- Midazolam (MIDA)
- Mirtazapine (MIRTA)
- Modafinil (MODA)
- Molecular fungal diagnostics, multiplex-PCR (PILZM)
- Molybdenum (MOLY)
- Morphine (MORPH)
- Mother milk (MOTH)
- testing of Insecticides, metals
- MRGN (MRGN)
- Multidrug-resistant gram negative pathogens
- MRSA/ORSA (MRSA)
- Methicillin or oxacillin-resistant staphylococcus aureus
- MTHFR polymorphism (MTHFR)
- 5.10-methylenetetrahydrofolate reductase gene, C677T mutation
- Mucopolysaccharidoses (MUCOSC)
- Mucormycosis (MUMYK)
- Mumps (MUMP)
- Paramyxovirus, serotype 1
- Munc-18 autoantibodies (MUNC)
- Muscle specific receptor tyrosine kinase autoantibodies
- MuSK antibodies
- Mycophenolate Mofetil (MYCOPH)
- Active metabolite: mycophenolic acid
- Mycoplasma genitalium (MG)
- Mycoplasma pneumoniae (MYCO)
- Mycosis (MYKOSE)
- Myelin-associated glycoprotein autoantibodies (MAG)
- Myoglobin in serum (MYOG)
- Myoglobin in urine (MYOGU)
- Myositis autoantibodies, basic panel (MYOSI)
- Mi-2a-, Mi-2b-, TIF1g-, MDA5-, NXP2-, SAE1-, Ku (86,72)-, PM100-, PM75-, Jo-1-, SRP-, PL-7-, PL-12-, EJ-, OJ-, Ro52-, HMGCR-, cN-1A-autoantibodies
- Myositis autoantibodies, supplementary panel
- (KS-, Zo-, Ha-autoantibodies)